NCT04345913 2026-03-19Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerNational Cancer Institute (NCI)Phase 1/2 Active not recruiting24 enrolled 24 charts
NCT03803761 2023-09-25A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast CancerNational Cancer Institute (NCI)Phase 1/2 Withdrawn